Biotechnology Reagents & Kits Market (2026 - 2033)

Biotechnology Reagents & Kits Market Summary

The increased use of testing kits such as cytometry-based methods for diagnosing and assessing the immune responses to COVID-19 had further surged the growth of this market during the pandemic. Recent advancements in the molecular biology arena and several engineering tools facilitated the development of new and advanced kits to cope with rising market demand. 

The growing focus on molecular biology research and technological advancements in genomic sequencing since the inception of the first revolutionary DNA sequencing technique has driven demand for biotechnology reagents & kits. In the past few years, several key developments have occurred across areas such as high-throughput sequencing, genome engineering, big data analysis & storage, and gene therapy.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The new development in high-throughput sequencing is helping in the reduction of costs related to DNA sequencing. As per a study published in the National Library of Medicine in September 2022, platforms such as Roche-454 GS Junior, Ion Torrent, and FLX+ can produce large amounts of data in less time and cost, which has made these technologies more accessible.

Moreover, during the COVID-19 pandemic, RT-PCR assay was the most widely used method for the detection of viral RNA in patient samples and several more assays were developed specifically to detect COVID-19. The Centers for Disease Control (CDC) also developed a separate test protocol after validating and comparing several kits used in the extraction of nucleic acids, which is an integral part of the COVID-19 testing workflow.

The huge demand for nucleic acid isolation and purification kits during the pandemic has led to a global shortage. However, by leveraging this opportunity, several companies undertook initiatives such as expanding production capacity, entering into distribution agreements, and launching new products to enhance their market positions. This also accelerated the entry of new players into the market, thereby boosting market growth. In October 2024, Illumina launched the MiSeq i100 Series, a new benchtop sequencing platform designed to deliver faster sequencing runs and simplified workflows, making genomic sequencing more accessible to research and clinical laboratories.

Market Dynamics

The biotechnology reagents & kits industry is expanding rapidly due to increasing investments in life sciences research, molecular diagnostics, genomics, proteomics, and biopharmaceutical development. Biotechnology reagents and kits are essential consumables used in applications such as nucleic acid extraction, PCR testing, next-generation sequencing (NGS), cell culture, gene editing, and protein analysis. The growing adoption of precision medicine, personalized therapeutics, and advanced diagnostic technologies has significantly increased demand for high-quality reagents and ready-to-use kits across research institutes, pharmaceutical companies, biotechnology firms, and clinical laboratories.

Analyst Perspective

The biotechnology reagents & kits market is positioned for sustained growth, supported by the increasing adoption of genomics, molecular diagnostics, cell and gene therapy research, and biopharmaceutical development. Rising investments in life sciences research, expanding applications of next-generation sequencing (NGS), and growing demand for precision medicine are creating strong demand for high-performance reagents and kits across research, clinical, and industrial settings. However, long-term market leadership will depend on companies' ability to deliver integrated, automation-compatible, and workflow-efficient solutions that improve reproducibility, reduce turnaround times, and support high-throughput applications. Vendors that combine innovation in reagent chemistry with advanced molecular and multi-omics technologies will be best positioned to capitalize on the growing complexity of biological research and the evolving needs of healthcare and biotechnology industries.

Kit Type Insights

The detection kit segment led the market with the largest revenue share of over 20.0% in 2025, driven by increasing use across various end-use settings, including healthcare, food and agriculture, industrial processing, and others. The increasing prevalence of diseases such as diabetes, cancer, infectious diseases, and genetic disorders is adding to the growth of this segment. According to the International Diabetes Federation (IDF) Diabetes Atlas 11th Edition, an estimated 589 million adults worldwide were living with diabetes in 2024, highlighting the growing need for diagnostic and disease-monitoring technologies.

The amplification kits segment is expected to grow at the fastest CAGR over the forecast period. The emergence of new diseases and the increasing prevalence of existing ones are driving the need for more advanced tools. Moreover, technological advancements in biotechnology and rising R&D investments are expected to drive growth in the segment. Several biotechnology companies have recently expanded their portfolios of PCR, qPCR, and isothermal amplification solutions to meet the growing demand for rapid, accurate nucleic acid detection. These developments reflect increasing investments in molecular diagnostics, infectious disease surveillance, and genomics research, which are expected to accelerate the adoption of amplification kits across research and clinical settings. 

Technology Insights

The cell culture segment led the market with the largest revenue share of 15.0% in 2025. It is considered one of the most important investigative techniques for investigating biochemistry, biology, and metabolism in diseased and wild-type cells. Therefore, there is an increasing demand for cell culture reagents by the research community. Furthermore, the comprehensive portfolios of cell culture media and reagents owned by companies are driving market growth. Moreover, advances in cell culture technology in drug discovery and development can further drive this segment's growth. For instance, due to their higher efficiency and other advantages, 3D culture models are now being adopted in place of 2D models in the early stages of drug discovery.

The sequencing reagents segment is anticipated to grow at a significant CAGR over the forecast period, driven by advancements in sequencing techniques. Next-Generation Sequencing (NGS) is now considered a reliable and powerful tool for characterizing cell lines used for the production of gene therapy, vaccines, and recombinant proteins. In addition, declining sequencing costs and the expansion of large-scale genomics initiatives are encouraging broader utilization of NGS technologies across research, clinical, and public health applications.

Tested Parameters Insights

The RNA segment led the market with the largest revenue share of 18% in 2025. Research on extracellular RNA for clinical diagnosis has increased in recent years. Companies and universities are entering the field of RNA-based therapeutics using transcriptomic technologies. Key industry participants are introducing new products to drive the market. For instance, in May 2024, QIAGEN introduced the Library Kit, QIAseq Multimodal DNA/RNA, enabling streamlined preparation of both DNA and RNA libraries from a single sample for next-generation sequencing applications. Such product innovations are expected to accelerate RNA-based research and therapeutic development, thereby driving growth in the RNA segment.

The DNA segment is anticipated to grow at a significant CAGR during the forecast period, driven by the increasing demand for DNA diagnostics technology. DNA testing has significant applications in newborn genetic screening, identity diagnostics & forensics, pharmacogenomics diagnostic testing, and drug metabolism, which can further boost this segment's growth. Furthermore, the growing adoption of precision medicine and companion diagnostics is increasing the need for accurate DNA analysis, thereby driving demand for DNA extraction, amplification, and sequencing reagents across clinical and research applications.

Purpose Insights

The on-site segment led the market with the largest revenue share of 60.0% in 2025, driven by rising utilization of Point-of-Care (POC) testing services. Several governmental and non-governmental organizations are also supporting POC testing services for their efficient operations. Efficient, timely POC testing, based on the availability of POC reagents, can further drive the segment's growth. On-site testing applications in the food and beverage industry also aided the market expansion. It includes on-site microbiological and enzymatic testing. Microbiological on-site testing is used the detect viruses, bacteria, and molds in food. Enzymatic on-site testing is used to measure constituents, such as acids, alcohols, and sugars, in foods. This test is essential when analyzing beverage and dairy products.

A wide variety of research reagents contribute to the growth of numerous scientific and medical fields. Laboratory reagents are employed in various assays and methodologies, such as Immunohistochemistry (IHC), cell culture, flow cytometry, cell selection, protein purification, immunodepletion, and others. Moreover, in vitro reagents are considered crucial in clinical chemistry and testing laboratories.

The laboratory segment is anticipated to grow at a significant CAGR during the forecast period, driven by extensive use of these products across academic research institutes, biotechnology companies, pharmaceutical laboratories, and clinical research organizations. These products are essential for a wide range of applications, including nucleic acid extraction, PCR, sequencing, cell culture, protein analysis, drug discovery, and biomarker research. The growing focus on genomics, proteomics, precision medicine, and biologics development has further increased the demand for high-quality laboratory reagents and kits. In addition, rising investments in life science research, expanding R&D activities, and the increasing adoption of advanced molecular biology techniques are expected to support the continued growth of this segment over the forecast period.

End-use Insights

The healthcare segment led the market with the largest revenue share of approximately 52.0% in 2025, driven by ongoing clinical trials, expanding genomic research, growing molecular diagnostic applications, and rising investments in precision medicine. Moreover, a shift in preferences toward molecular diagnostics and personalized medicine has increased mergers and collaborations to develop novel technologies, thereby driving demand for advanced products in the healthcare sector. In addition, the rising prevalence of chronic, infectious, and genetic disorders is increasing the demand for accurate diagnostic testing and targeted treatment, thereby driving the adoption of biotechnology reagents and kits across hospitals, clinical laboratories, and healthcare facilities.

The industrial processing segment is expected to grow at the fastest CAGR over the forecast period. The increasing use of biotechnology in the production of industrial enzymes and chemicals to develop more advanced, sustainable materials is expected to drive growth in this segment. For instance, the process of bio-cementation is used in the construction industry, where bacteria precipitate calcium carbonate within concrete. The process helps in making it stronger and more durable.

Regional Insights

North America dominated the global biotechnology reagents & kits market with the largest revenue share of approximately 37.0% in 2025. The presence of several key players actively developing technologically advanced novel products, coupled with the introduction of innovative products by emerging start-ups, has significantly contributed to the dominance of the region.

To learn more about this report, Download Free Sample Report

U.S. Biotechnology Reagents & Kits Market

The biotechnology reagents & kits market in the U.S. accounted for the largest market revenue share in North America in 2025. U.S.-based players and organizations are continually engaged in high-quality life science research, molecular diagnostics, and precision medicine initiatives, thereby positively impacting ancillary markets. Various strategic initiatives by key companies to maintain regional presence and market share continue to support market growth. For instance, in July 2025, Waters Corporation announced a USD 17.5 billion merger with the Biosciences & Diagnostic Solutions business of Becton, Dickinson and Company. 

Asia Pacific Biotechnology Reagents & Kits Market

The biotechnology reagents & kits market in the Asia Pacific is expected to grow at the fastest CAGR of approximately 12.0% during the forecast period. The growing disposable income, rising healthcare expenditure, improved diagnostics & therapeutic infrastructure, and increased research into the development of effective therapeutics are key factors driving market growth in the Asia Pacific. For instance, in August 2024, the Government of India approved the establishment of the BioE3 (Biotechnology for Economy, Environment, and Employment) policy to strengthen the country's biotechnology ecosystem by promoting biomanufacturing, precision therapeutics, and advanced biotechnology research. Such initiatives are expected to accelerate innovation, expand research capabilities, and increase the adoption of biotechnology reagents and kits across the region. 

Key Biotechnology Reagents & Kits Company Insights

The biotechnology reagents & kits industry is expected to witness tremendous growth over the forecast period. Key players in the market are actively pursuing technological collaborations, expanding product portfolios, and increasing R&D investments to gain market share. The new product developments undertaken by key companies are positively impacting market growth and enhancing their competitiveness.

Key Biotechnology Reagents & Kits Companies

The following key companies have been profiled for this study on the biotechnology reagents & kits market.

• Thermo Fisher Scientific Inc.

• QIAGEN

• New England Biolabs

• Illumina, Inc.

• Agilent Technologies, Inc.

• Bio-Rad Laboratories, Inc.

• F. Hoffmann-La Roche Ltd.

• Merck KGaA, Darmstadt, Germany

• Promega Corporation.

• Takara Bio, Inc.

• LGC Limited

• TOYOBO CO., LTD.

Recent Developments

• In September 2025, Thermo Fisher Scientific Inc. launched Gibco Efficient-Pro Medium (+) Insulin, a next-generation cell culture medium developed for insulin-dependent CHO cell lines used in biologics manufacturing. The product enhanced cell culture productivity and strengthened Thermo Fisher's leadership in biotechnology reagents and bioprocessing solutions.

• In April 2024, Bio-Rad Laboratories, Inc. launched the ddPLEX ESR1 Mutation Detection Kit, a digital PCR-based assay designed for highly sensitive detection of ESR1 mutations in breast cancer research. The launch expanded the company's molecular analysis portfolio and highlighted the growing demand for advanced reagents and kits used in oncology and precision medicine applications. 

Global Biotechnology Reagents & Kits Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biotechnology reagents & kits market report based on kit type, technology, tested parameters, purpose, end use, and region:

• Kit Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Purification Kits

  • Amplification Kits

  • Detection Kits

  • Isolation Kits

  • Others

• Technology Outlook (Revenue, USD Billion, 2021 - 2033)

  • LAMP Technology

  • PCR

  • Cell Culture

  • Sequencing

  • Chromatography

  • Electrophoresis

  • Flow Cytometry

  • Other Technologies

• Tested Parameters Outlook (Revenue, USD Billion, 2021 - 2033)

  • DNA

  • RNA

  • Enzymes

  • Proteins

  • Others

• Purpose Outlook (Revenue, USD Billion, 2021 - 2033)

  • On-site

  • Laboratory

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Healthcare

  • Food & Agriculture

  • Natural Resources & Environment

  • Industrial Processing

  • Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait